KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Acquisitions (2016 - 2025)

Boston Scientific's Acquisitions history spans 16 years, with the latest figure at $89.0 million for Q4 2025.

  • For Q4 2025, Acquisitions fell 97.4% year-over-year to $89.0 million; the TTM value through Dec 2025 reached $1.6 billion, down 65.67%, while the annual FY2025 figure was $1.6 billion, 65.67% down from the prior year.
  • Acquisitions for Q4 2025 was $89.0 million at Boston Scientific, down from $256.0 million in the prior quarter.
  • Across five years, Acquisitions topped out at $3.4 billion in Q4 2024 and bottomed at $47.0 million in Q1 2024.
  • The 5-year median for Acquisitions is $509.0 million (2023), against an average of $740.2 million.
  • The largest YoY upside for Acquisitions was 2002.08% in 2025 against a maximum downside of 97.4% in 2025.
  • A 5-year view of Acquisitions shows it stood at $244.0 million in 2021, then crashed by 70.9% to $71.0 million in 2022, then soared by 1016.9% to $793.0 million in 2023, then skyrocketed by 331.02% to $3.4 billion in 2024, then crashed by 97.4% to $89.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Acquisitions are $89.0 million (Q4 2025), $256.0 million (Q3 2025), and $1.0 billion (Q2 2025).